Skip to main content

Advertisement

SpringerLink
Log in

Short-term and long-term survival of interval breast cancers taking into account prognostic features

  • Original paper
  • Published:
Cancer Causes & Control Aims and scope Submit manuscript

Abstract

Purpose

The aim of this population-based study was to estimate short-term and long-term survival of interval breast cancers and to compare them to clinically detected cancers, taking into account prognostic features.

Methods

This study included all interval cancers and clinically detected cancers diagnosed in the Loire-Atlantique population-based cancer registry from 2000 to 2010 in women aged 50–76 years. We used the Pohar-Perme method to estimate 5- and 10 year net survival rates and a flexible parametric model to compare interval cancer and clinically detected cancer prognosis with and without adjustment for the main prognostic factors (age, stage, histological grade, and phenotype).

Results

This study included 813 interval cancers and 1,354 clinically detected cancers. Interval cancers were diagnosed at a significantly less advanced stage than clinically detected cancers, but more often with a triple-negative phenotype. Interval cancer age-standardised net survival was 88.0% at 5 years (95% CI 84.9–91.2) and 81.7% at 10 years (95% CI 76.9–86.9), whereas clinically detected cancer age-standardised net survival was 77.8% (95% CI 75.1–80.6) and 64.6% (95% CI 60.7–68.7), respectively. After adjustment for covariates, survival no longer differed between interval cancers and clinically detected cancers at 5 and 10 years.

Conclusion

Although the interval cancer net survival rate was higher, interval cancers had a similar short-term and long-term prognosis than clinically detected cancers after taking into account the main prognostic factors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Binder-Foucard F, Bossard N, Delafosse P, Belot A, Woronoff A-S, Remontet L et al (2014) Cancer incidence and mortality in France over the 1980-2012 period: solid tumors. Rev Epidemiol Sante 62(2):95–108

    Article  CAS  Google Scholar 

  2. Cowan WK, Angus B, Gray JC, Lunt LG, al-Tamimi SR (2000) A study of interval breast cancer within the NHS breast screening programme. J Clin Pathol 53(2):140–146

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Caumo F, Vecchiato F, Strabbioli M, Zorzi M, Baracco S, Ciatto S (2010) Interval cancers in breast cancer screening: comparison of stage and biological characteristics with screen-detected cancers or incident cancers in the absence of screening. Tumori 96(2):198–201

    PubMed  Google Scholar 

  4. Kirsh VA, Chiarelli AM, Edwards SA, O’Malley FP, Shumak RS, Yaffe MJ et al (2011) Tumor characteristics associated with mammographic detection of breast cancer in the Ontario breast screening program. J Natl Cancer I 103(12):942–950

    Article  Google Scholar 

  5. Rayson D, Payne JI, Abdolell M, Barnes PJ, MacIntosh RF, Foley T et al (2011) Comparison of clinical-pathologic characteristics and outcomes of true interval and screen-detected invasive breast cancer among participants of a Canadian breast screening program: a nested case-control study. Clin Breast Cancer 11(1):27–32

    Article  PubMed  Google Scholar 

  6. Chiarelli AM, Edwards SA, Sheppard AJ, Mirea L, Chong N, Paszat L et al (2012) Favourable prognostic factors of subsequent screen-detected breast cancers among women aged 50–69. Eur J Cancer Prev 21(6):499–506

    Article  PubMed  Google Scholar 

  7. Domingo L, Blanch J, Servitja S, Corominas JM, Murta-Nascimento C, Rueda A et al (2013) Aggressiveness features and outcomes of true interval cancers: comparison between screen-detected and symptom-detected cancers. Eur J Cancer Prev 22(1):21–28

    Article  PubMed  Google Scholar 

  8. Renart-Vicens G, Puig-Vives M, Albanell J, Castañer F, Ferrer J, Carreras M et al (2014) Evaluation of the interval cancer rate and its determinants on the Girona Health Region’s early breast cancer detection program. BMC Cancer 14:558

    Article  PubMed  PubMed Central  Google Scholar 

  9. José Bento M, Gonçalves G, Aguiar A, Antunes L, Veloso V, Rodrigues V (2014) Clinicopathological differences between interval and screen-detected breast cancers diagnosed within a screening programme in Northern Portugal. J Med Screen 21(2):104–109

    Article  PubMed  Google Scholar 

  10. Baré M, Torà N, Salas D, Sentís M, Ferrer J, Ibáñez J et al (2015) Mammographic and clinical characteristics of different phenotypes of screen-detected and interval breast cancers in a nationwide screening program. Breast Cancer Res Treat 154(2):403–415

    Article  PubMed  Google Scholar 

  11. Brekelmans CT, Peeters PH, Deurenberg JJ, Collette HJ (1995) Survival in interval breast cancer in the DOM screening programme. Eur J Cancer 31A(11):1830–1835

    Article  CAS  PubMed  Google Scholar 

  12. Shen Y, Yang Y, Inoue LYT, Munsell MF, Miller AB, Berry DA (2005) Role of detection method in predicting breast cancer survival: analysis of randomized screening trials. J Natl Cancer I 97(16):1195–1203

    Article  Google Scholar 

  13. Lawrence G, O’Sullivan E, Kearins O, Tappenden N, Martin K, Wallis M (2009) Screening histories of invasive breast cancers diagnosed 1989–2006 in the West Midlands, UK: variation with time and impact on 10-year survival. J Med Screen 16(4):186–192

    Article  PubMed  Google Scholar 

  14. Nagtegaal ID, Allgood PC, Duffy SW, Kearins O, Sullivan EO, Tappenden N et al (2011) Prognosis and pathology of screen-detected carcinomas: how different are they? Cancer 117(7):1360–1368

    Article  PubMed  Google Scholar 

  15. Raja MA, Hubbard A, Salman AR (2001) Interval breast cancer: is it a different type of breast cancer? Breast 10(2):100–108

    Article  CAS  PubMed  Google Scholar 

  16. Kalager M, Tamimi RM, Bretthauer M, Adami H-O (2012) Prognosis in women with interval breast cancer: population based observational cohort study. BMJ 345:e7536

    Article  PubMed  PubMed Central  Google Scholar 

  17. Holmberg LH, Tabar L, Adami HO, Bergström R (1986) Survival in breast cancer diagnosed between mammographic screening examinations. Lancet 2(8497):27–30

    Article  CAS  PubMed  Google Scholar 

  18. Peeters PH, Verbeek AL, Hendriks JH, Holland R, Mravunac M, Vooijs GP (1989) The occurrence of interval cancers in the Nijmegen screening programme. Br J Cancer 59(6):929–932

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Frisell J, von Rosen A, Wiege M, Nilsson B, Goldman S (1992) Interval cancer and survival in a randomized breast cancer screening trial in Stockholm. Breast Cancer Res Treat 24(1):11–16

    Article  CAS  PubMed  Google Scholar 

  20. Schroën AA, Wobbes T, van der Sluis RF (1996) Interval carcinomas of the breast: a group with intermediate outcome. J Surg Oncol 63(3):141–144

    Article  PubMed  Google Scholar 

  21. Collins S, Woodman CB, Threlfall A, Prior P (1998) Survival rates from interval cancer in NHS breast screening programme. BMJ 316(7134):832–833

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Bordás P, Jonsson H, Nyström L, Lenner P (2007) Survival from invasive breast cancer among interval cases in the mammography screening programmes of northern Sweden. Breast 16(1):47–54

    Article  PubMed  Google Scholar 

  23. Zackrisson S, Janzon L, Manjer J, Andersson I (2007) Improved survival rate for women with interval breast cancer—results from the breast cancer screening programme in Malmö, Sweden 1976–1999. J Med Screen 14(3):138–143

    Article  PubMed  Google Scholar 

  24. Perme MP, Stare J, Estève J (2012) On estimation in relative survival. Biometrics 68(1):113–120

    Article  PubMed  Google Scholar 

  25. Roche L, Danieli C, Belot A, Grosclaude P, Bouvier A-M, Velten M et al (2013) Cancer net survival on registry data: use of the new unbiased Pohar-Perme estimator and magnitude of the bias with the classical methods. Int J Cancer 132(10):2359–2369

    Article  CAS  PubMed  Google Scholar 

  26. Corazziari I, Quinn M, Capocaccia R (2004) Standard cancer patient population for age standardising survival ratios. Eur J Cancer 40(15):2307–2316

    Article  PubMed  Google Scholar 

  27. Nelson CP, Lambert PC, Squire IB, Jones DR (2007) Flexible parametric models for relative survival, with application in coronary heart disease. Stat Med 26(30):5486–5498

    Article  PubMed  Google Scholar 

  28. Perry N, Broeders M, de Wolf C, Törnberg S, Holland R, von Karsa L (2006) European guidelines for quality assurance in breast cancer screening and diagnosis, 4th edn. Office for Official Publications of the European Communities, Luxembourg

    Google Scholar 

  29. Santé Publique France (2013) Performance indicators of the breast cancer screening program, in Loire-Atlantique, from 2008 to 2010. http://invs.santepubliquefrance.fr/content/download/67068/258242/version/1/file/44_Loire_Atlantique_CUMUL2010.xls. Accessed 13 Oct 2016

  30. Exbrayat C, Poncet F, Guldenfels C, Soler-Michel P, Allioux C, Barraud-Krabe M (2012) Sensibilité et spécificité du programme de dépistage organisé du cancer du sein à partir des données de cinq départements français, 2002–2006. BEH 35–37:404–406

    Google Scholar 

  31. Weber RJP, van Bommel RMG, Louwman MW, Nederend J, Voogd AC, Jansen FH et al (2016) Characteristics and prognosis of interval cancers after biennial screen-film or full-field digital screening mammography. Breast Cancer Res Treat 158(3):471–483

    Article  PubMed  Google Scholar 

  32. Vitak B, Stål O, Månson JC, Thomas BA, Arnesson LG, Ekelund L et al (1997) Interval cancers and cancers in non-attenders in the Ostergötland Mammographic Screening Programme. Duration between screening and diagnosis, S-phase fraction and distant recurrence. Eur J Cancer 33(9):1453–1460

    Article  CAS  PubMed  Google Scholar 

  33. McGuire WL (1978) Hormone receptors: their role in predicting prognosis and response to endocrine therapy. Semin Oncol 5(4):428–433

    CAS  PubMed  Google Scholar 

  34. Russo J, Russo IH (1994) Toward a physiological approach to breast cancer prevention. Cancer Epidemiol Biomark Prev 3:353–364

    CAS  Google Scholar 

  35. Lapidus RG, Nass SJ, Davidson NE (1998) The loss of estrogen and progesterone receptor gene expression in human breast cancer. J Mammary Gland Biol 3(1):85–94

    Article  CAS  Google Scholar 

  36. Jatoi I, Chen BE, Anderson WF, Rosenberg PS (2007) Breast cancer mortality trends in the United States according to estrogen receptor status and age at diagnosis. J Clin Oncol 25(13):1683–1690

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

We would like to thank those who provided data to the registry: pathologists, oncologists, public and private hospital medical data processing departments, and medical practitioners as well as the medical services of the national health insurance program. National financial supports for routine collection of data by cancer registry are Santé Publique France and Institut National du Cancer. Collection of breast cancer mode of detection was supported specifically by Santé Publique France.

Author information

Authors and Affiliations

  1. Loire-Atlantique/Vendée Cancer Registry, Plateau des écoles, 50 route de St Sébastien, 44093, Nantes Cedex 1, France

    Solenne Delacour-Billon, Anne Laure Mathieu-Wacquant, Nathalie Auffret, Sophie Amossé, Anne Cowppli-Bony & Florence Molinié

  2. Institut de Cancérologie de l’Ouest, Site René Gauducheau, Boulevard Jacques Monod, 44805, St Herblain Cedex, France

    Mario Campone

  3. CAP Santé Plus 44, 50 route de St Sébastien, CS 96531, 44265, Nantes, France

    Corinne Allioux

Authors
  1. Solenne Delacour-Billon
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anne Laure Mathieu-Wacquant
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mario Campone
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Nathalie Auffret
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sophie Amossé
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Corinne Allioux
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Anne Cowppli-Bony
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Florence Molinié
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Solenne Delacour-Billon.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

For this type of study, formal consent is not required.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Delacour-Billon, S., Mathieu-Wacquant, A.L., Campone, M. et al. Short-term and long-term survival of interval breast cancers taking into account prognostic features. Cancer Causes Control 28, 69–76 (2017). https://doi.org/10.1007/s10552-016-0836-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10552-016-0836-0

Keywords

Search

Navigation